Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question

J Clin Oncol. 2006 May 20;24(15):2225-6. doi: 10.1200/JCO.2005.05.3785.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Aminoquinolines
  • Aniline Compounds
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics
  • Erlotinib Hydrochloride
  • Gefitinib
  • Humans
  • Mutation
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Organic Chemicals / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use
  • Quinazolines / therapeutic use

Substances

  • Aminoquinolines
  • Aniline Compounds
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Organic Chemicals
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Gefitinib
  • EKB 569